12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Company News  |  Deals

Oxford GlycoSciences, Searle deal

The companies renegotiated their 1997 license agreement for OGS's OGT 918, an oral glucosyltransferase inhibitor, in order to reduce royalties...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >